[Matrix metalloproteinases and their inhibitors, modulators of neuro-immune interactions and of pathophysiological processes in the nervous system].
The matrix metalloproteinases (MMPs) belong to a growing family of Zn2+-dependent endopeptidases, secreted or membrane-bound (MT-MMP), that regulate or degrade by proteolytic cleavage protein components of the extracellular matrix, cytokines, chemokines, cell adhesion molecules and a variety of membrane receptors. MMP activity is counterbalanced by their physiological inhibitors, the tissue inhibitors of MMPs (TIMPs), a family of 4 secreted multifunctional proteins that have growth promoting activities. In physiological conditions MMP activity is tightly regulated and altered MMP regulation is associated with pathological processes including inflammation, cell proliferation, cell death and tissue remodeling. The MMP/TIMP system is involved in the development and function of cells of the immune system by promoting their differentiation, activation, migration across basement membranes and tissues. In the last years, data has accumulated indicating that the MMP/TIMP system is expressed in the nervous system where it regulates neuro-immune interactions and plays a major role in pathophysiological processes. In this review, we present recent in vivo and in vitro studies that highlight the contribution of the MMP/TIMP system to various diseases of the nervous system, involving blood brain barrier breakdown, neuroinflammation, glial reactivity, neuronal death, reactive plasticity, and to developmental and physiological processes including cell migration, axonal sprouting and neuronal plasticity. This review also alludes to the beneficial effects of synthetic MMP inhibitors in different animal models of neuropathology. In all, a further understanding of the role of MMPs and TIMPs in the nervous system should contribute to unravel mechanisms of neuronal plasticity and pathology and set the basis of new therapeutic strategies in nervous system disorders based on the development of synthetic MMP inhibitors.
Khrestchatisky
Michel
M
FRE CNRS 2533, Université de la Méditerranée, Faculté de Médecine, IFR Jean Roche, 27 Bd Jean Moulin, 13385 Marseille. khrestchatisky.m@jean-roche.univ-mrs.fr
Jourquin
Jérôme
J
Ogier
Crystel
C
Charton
Gérard
G
Bernard
Anne
A
Tremblay
Evelyne
E
Rivera
Santiago
S
D000818:Animals; D001812:Blood-Brain Barrier / Q000502:physiology; D004195:Disease Models, Animal; D006801:Humans; D008666:Metalloendopeptidases / Q000378:metabolism*; D009422:Nervous System Diseases / Q000201:enzymology / Q000276:immunology* / Q000503:physiopathology*; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism*
D019714:Tissue Inhibitor of Metalloproteinases; D008666:Metalloendopeptidases